Skip to main content

Advertisement

Table 1 Overview on HIV-2 samples analyzed

From: The efficiency of Vpx-mediated SAMHD1 antagonism does not correlate with the potency of viral control in HIV-2-infected individuals

Subject Clones CD4a PVLb Groupc R5/X4d Group vpxallelese References
RH2-3 2C5/8A3 770 bql aviremic R5 A 3/3 [26–30]
RH2-13 1D4/5C1 900 bql aviremic R5 A 3/3 [26–30]
RH2-14 1B1/1D1 550 bql aviremic R5 A 3/3 [26–30]
RH2-22 2C2/1B4 670 bql aviremic R5 B 4/4 [26–30]
RH2-1 A8/D8 240 >500 viremic R5 A 3/6 [26–30]
RH2-5 2D11/2F10 120 110,000 viremic R5 A 3/3 [26–30]
RH2-7 B3/D6 10 >500 viremic R5 A 3/3 [26–30]
RH2-21 2B2/2F9 60 59,000 viremic n.k. A 3/3 [26–30]
RH2-24 2F11 70 330,000 viremic R5/X4 A 3 [26–30]
RH2-26 1C1 10 >500 viremic R5/X4 A 8 [26–30]
PH2.1 C12/E6 200 >500 viremic n.k. A 3/3 [30, 31]
  1. a Absolute CD4 T cell counts per μl blood.
  2. b Copies of plasma viral RNA per milliliter.
  3. c Grouped based on VLs.
  4. d Usage of CCR5 or CXCR4 for viral entry.
  5. e Number of vpx alleles sequenced per biological HIV-2 clone.
  6. Abbreviations: PVL plasma viral load, Bql below quantifiable limit, n.k. not known.
Back to article page